Improving treatment for acute myeloid leukemia with specific genetic changes
Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD
This study is looking for better ways to help people with acute myeloid leukemia who have a specific genetic change called FLT3-ITD, by figuring out why some treatments aren't working and finding new strategies to make them more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baltimore VA Medical Center NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10911077 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of FLT3 inhibitors in treating acute myeloid leukemia (AML), particularly in patients with a specific genetic alteration known as FLT3-ITD. The study investigates the mechanisms behind resistance to current treatments and aims to identify ways to overcome this resistance. By understanding how FLT3-ITD affects cancer cell signaling and survival, the research seeks to develop more effective therapeutic strategies for patients. This could involve targeting additional pathways that contribute to the cancer's growth and survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, particularly those with the FLT3-ITD genetic alteration.
Not a fit: Patients with acute myeloid leukemia who do not have the FLT3-ITD mutation may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with acute myeloid leukemia who have the FLT3-ITD mutation.
How similar studies have performed: Previous research has shown promise in targeting FLT3 mutations in AML, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Baltimore, United States
- Baltimore VA Medical Center — Baltimore, United States (Active)
Researchers
- Principal investigator: Baer, Maria R — Baltimore VA Medical Center
- Study coordinator: Baer, Maria R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.